The global high resolution melting analysis market size was valued at USD 75.3 million in 2016 and is expected to grow at a CAGR of 9.8% during the forecast period. Increasing investment in R&D, growing applications of this technology in epigenetics, and mutation scanning are some of the factors propelling the market growth. Benefits such as no use of probes, closed tube system, prevention of post-PCR sample contamination, and high accuracy of melting profile analysis are driving the HRM analysis market growth.
The market dynamics indicate that various players operating in this space compete, based on product specifications, such as reagents, software & instrument capabilities, and prices. The technology used to manufacture, quality of the product, and sample processing capacity are the key variables expected to impact the usage rates of these products. Increasing collaboration between government bodies and major players to introduce technologically advanced products and reduce overall healthcare costs is expected to further intensify the HRM analysis market competition.
Factors such as growing prevalence of chronic diseases, rising demand for personalized medicine and favorable government initiatives are expected to have a positive impact on the HRM analysis market. Personalized medicine, which is also known as precision medicine, is an innovative and powerful approach to prevent and treat the disease after considering the differences in different genetic combinations, lifestyle, and environmental factors.
Recent developments in the field of next-generation sequencing (NGS), genomics, and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approached several treatment options designed to meet the requirements of a specific genetic makeup or a genomic profile of a patient’s tumor. This in turn is anticipated to boost demand for HRM analysis over the forecast period.
Based on product type, HRM analysis market is segmented into instruments, reagents and software. High Resolution Melting (HRM) reagents emerged as one of the high potential product segments of HRM analysis market in 2014. This segment is anticipated to expand at CAGR of 12.0% between 2015 and 2022. Cost-effectiveness and increasing research regarding cancer, HIV, and other genetic disorders by universities and academic researchers are amongst the key factors that can be attributed for the segment’s high share.
HRM instruments segment is expected to be the largest segment of HRM analysis market over the forecast period. Growing application of HRM analysis for identification of candidate predisposition genes, DNA mapping, mutation discovery, and HLA typing are amongst the few factors expected to boost the segment growth. Continuously growing clinical industry has attracted private investors and resulted in increased government scrutiny around validation of clinical trials. The rate of investments in capital instrumentation is growing, especially in develop geographies like North America and Europe. This in turn is expected to bolster demand for HRM analysis market. This segment is 66.6% share in 2014.
The HRM software generally used in this market are LightCycler 480 Gene Scanning Software by Roche Diagnostics and high resolution melting (HRM) analysis software v2.0, software v3.0.1, software v1.0, & software v3.1 by Thermo Fisher Scientific Corporation. Rising awareness regarding the limitations of conventional systems over HRM in real-time and thermos optical analysis is one of the key factors expected to positively reinforce high resolution melting market growth. Software segment is expected to witness second fastest growth during the forecast period.
Academic research dominated the overall market in terms of revenue share of 77.01% in 2014 owing to the growing demand for simple and efficient molecular diagnostics and technological advancements from the traditional genotyping by the use of labeled probes for high-resolution melt analysis technique. Moreover, rising demand for fast and powerful genotype analysis of larger samples for massive scale genotyping projects is expected to positively reinforce the demand for high resolution melting (HRM) analysis market over the forecast period.
High growth opportunities in the biotechnology research, well-established reimbursement policies, growing government investments in academic institutions. and favorable regulatory framework are key factors fueling the growth of academic research segment. Moreover, according to the OECD, there has been a significant growth in the number of patents issued in the field of biotechnology owing to the importance provided to intellectual property and development in developments in the fields of molecular biology, biotechnology, and medicine is expected to increase demand for HRM products in academic research segment.
Clinical diagnostics is anticipated to be the fastest growing segment in HRM analysis market. Growing laboratory automation is one of the primary reasons for the rapid growth of this segment. According to the data published by The National Center for Biotechnology Information in 1998, mutation in the BRCA1 & BRCA2 genes leads to an increased susceptibility to breast or other cancers. High Resolution Melting analysis method proved to be suitable for detecting over 400 gene mutations in a sample for cancer detection. In addition, increasing prevalence of diseases such as cancer, HIV, AIDS, sickle cell, and gastroesophageal reflux diseases is expected to positively reinforce the demand for HRM analysis products in clinical labs and in turn boosting revenue growth of clinical diagnostic end use segment.
North America accounted for the largest market share of 41.6% in 2014. Key factors attributing to its high revenue share are high investment in research and development, presence of high quality healthcare infrastructure, availability of better reimbursement options, and. technological advancements. Furthermore, high awareness about different diagnostic tools available and associated benefits are the key forces impacting overall HRM analysis market growth.
Asia Pacific region is expected to be the fastest growing market over the forecast period. Key factors contributing to it are high population growth, increase in number of cancer cases and other chronic diseases leading to high unmet medical needs. Furthermore, growth of the overall in vitro diagnostics market in this region is expected to serve as a high impact rendering driver over the forecast period
Europe is anticipated to be the second largest market with revenue share of 37.8% in 2014. Increasing public and private investment in R&D, higher international R&D investment, increasing demand for advanced technology in research instruments are some of the key factors expected to boost the revenue growth. Germany is the fastest growing HRM analysis market in Europe, expanding at CAGR of 10.1% between 2015 and 2022. Germany ranks 20th on the list of countries for ease of doing business. According to the World Bank, Germany’s total healthcare expenditure was estimated to be nearly 11.3% of GDP. Increasing government investment owing to growing public finances, structural reforms, robust institutional framework, and rising competitiveness are amongst the few factors responsible for driving the HRM market growth over the forecast period
Some companies operating in the global HRM analysis market are Idaho Technology, Inc., Thermo Fisher Scientific Corporation, Roche Molecular Systems, Kapa Biosystems, Qaigen, Bio - Rad Laboratories and PREMIER Biosoft. HRM analysis market is oligopolistic in nature and has few companies accounting for maximum share. The manufacturers of HRM analysis devices face fierce competition and are focused on enhancing their customer pool through both inorganic and organic growth.
Attribute |
Details |
Base year for estimation |
2015 |
Actual estimates/Historical data |
2012 - 2015 |
Forecast period |
2016 - 2022 |
Market representation |
Revenue in USD Million and CAGR from 2015 to 2022 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
Country scope |
U.S., Canada, Germany, France, UK, China, Japan, Brazil, South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis on the industry trends in each of the sub-segments from 2012 to 2022. For the purpose of this study, Grand View Research has segmented the global high resolution Melting Analysis market report on the basis of product, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2012 - 2022)
Reagents
Instruments
Software
End-Use Outlook (Revenue, USD Million, 2012 - 2022)
Academic Research
Clinical Diagnostics
Application Outlook (Revenue, USD Million, 2012 - 2022)
Detection of Acquired Mutations/Mutation Scanning/SNP Typing
Microbial Species Identification
Zygosity Testing
Epigenetics/Methylation Profiling
Regional Outlook (Revenue, USD Million, 2012 - 2022)
North America
U.S.
Canada
Europe
UK
France
Germany
Asia Pacific
Japan
China
Latin America
Brazil
MEA
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.